Macquarie Group
AXDX

Macquarie Group’s Accelerate Diagnostics AXDX Stock Holding History

Macquarie Group’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-838
Closed -$12K – 2574
2022
Q1 		$12K Hold
838
– – ﹤0.01% 2485
2021
Q4 		$44K Sell
838
-359
-30% -$20K ﹤0.01% 2193
2021
Q3 		$70K Buy
1,197
+736
+160% +$48K ﹤0.01% 2101
2021
Q2 		$37K Buy
+461
New +$36.6K ﹤0.01% 2225

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Macquarie Group's AXDX Position: Q2 2022 in Review

Macquarie Group sold out of Accelerate Diagnostics (AXDX) in Q2 2022, closing a stake of 838 shares — an estimated $12K sold.

Macquarie Group first reported a position in AXDX in Q2 2021 and held it in 4 quarters. The position peaked at $70K in Q3 2021. 74 funds tracked by Wall St. Rank hold AXDX as of Q2 2022.

  • Macquarie Group reported no remaining Accelerate Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Macquarie Group sold 838 Accelerate Diagnostics shares in Q2 2022, an estimated $12K.
  • Macquarie Group first reported a position in Accelerate Diagnostics in Q2 2021 and held it in 4 quarters.
  • Macquarie Group's Accelerate Diagnostics position peaked at $70K in Q3 2021.
  • 74 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2022.

Based on Macquarie Group's 13F filing for Q2 2022, filed 15 Aug 2022.